BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension in the U.S. AstraZeneca has announced that the U.S. Food and Drug Administration has approved BAXFENDY for the treatment…
Gossamer Bio Reports Q1 2026 Financial Results and Highlights Recent Business Progress Gossamer Bio has reported its financial results for the first quarter ended March 31, 2026, while also providing…
Parabilis Medicines Partners With Regeneron Pharmaceuticals to Develop Antibody-Helicon™ Conjugates Across Multiple Diseases Parabilis Medicines has entered into a major strategic research collaboration with Regeneron Pharmaceuticals aimed at advancing a…
Agenus Publishes Promising Phase 1b Data for Botensilimab and Balstilimab Combination in Advanced Liver Cancer Agenus has announced the publication of new clinical data highlighting the potential of its investigational…
Lantern Pharma Reports First Quarter 2026 Results While Expanding AI-Driven Oncology and Commercial AI Platform Strategy Lantern Pharma reported operational highlights and financial results for the first quarter ended March…
Genentech Receives FDA Approval for Tecentriq in ctDNA-Guided Treatment of Muscle-Invasive Bladder Cancer Genentech announced that the U.S. Food and Drug Administration has approved both Tecentriq and Tecentriq Hybreza as…
Natera Receives FDA Approval for Signatera CDx as First Blood-Based MRD Companion Diagnostic in Muscle-Invasive Bladder Cancer Natera announced that the U.S. Food and Drug Administration has approved Signatera CDx…
Amylyx Publishes Phase 2 HELIOS Trial Results Showing Continued Benefits of AMX0035 in Wolfram Syndrome Amylyx Pharmaceuticals announced that detailed Week 24 and Week 48 findings from the Phase 2…
ICUS Supports New Sonography Training Standards Expanding Education in Contrast Enhanced Ultrasound International Contrast Ultrasound Society has expressed strong support for newly proposed accreditation standards that could significantly expand education…
Bayer Launches Midol in Motion Campaign to Support PMS Symptom Relief Through Movement and Education Bayer has announced the launch of “Midol in Motion,” a new awareness and education campaign…
Enveric Biosciences Reports First Quarter 2026 Results and Advances Non-Hallucinogenic Neuroplastogen Pipeline Enveric Biosciences reported financial results for the first quarter ended March 31, 2026, while also providing an extensive…
Kraken Regen Launches Advanced Collagen Platform Technology to Support Regenerative Medicine Research Kraken Regen has announced the launch of its new Collagen Platform Technology, introducing a high-purity collagen biomaterial engineered…